Racemic Ketamine vs Esketamine: Pharmacological Comparison

Racemic ketamine and esketamine are pharmacologically related but not identical, and the differences affect dosing, cost, insurance coverage, and which conditions each is approved to treat. This racemic ketamine vs esketamine pharmacological comparison breaks down how the two forms differ at the receptor level and what that means for someone weighing treatment options.

Ketamine is a chiral molecule, meaning it exists as two mirror-image forms called enantiomers: S-ketamine and R-ketamine, also known as arketamine. Racemic ketamine is an equal mixture of both. Esketamine is the isolated S-enantiomer, sold under the brand name Spravato. Racemic ketamine has been used in medicine since 1970, primarily as an anesthetic, while the U.S. Food and Drug Administration approved esketamine in 2019 specifically for treatment-resistant depression.

The core distinction is receptor binding. Esketamine binds more tightly to the NMDA receptor, the primary molecular target behind ketamine's antidepressant and anesthetic effects, which makes it more potent per milligram. Higher potency does not automatically translate into greater clinical effectiveness, and the two forms differ in ways that go beyond simple receptor affinity.

Ketamine's chirality is the starting point for every other difference between the two forms. Because S-ketamine and R-ketamine are mirror images of each other, they interact with the same receptors slightly differently, similar to how a left hand and a right hand fit differently into the same glove.

Racemic ketamine, the form used in anesthesia since the 1970s and in psychiatric research since the early 2000s, contains both enantiomers in equal parts. The foundational depression trials, including the Yale study in 2000 and the National Institute of Mental Health study in 2006 described in our history of ketamine, all used this racemic form.

Esketamine was isolated and developed separately by Janssen Pharmaceuticals, which markets it as Spravato. The FDA approved it in 2019 for treatment-resistant depression and in 2020 for major depressive disorder with acute suicidal ideation. Arketamine, the R-enantiomer left out of Spravato, is not currently an approved product but is being studied on its own, as discussed below.

According to StatPearls, a peer-reviewed clinical reference published through the National Center for Biotechnology Information, these enantiomers differ enough in receptor affinity, opioid activity, and metabolism to produce meaningfully different clinical profiles despite sharing a common mechanism of action.

Racemic ketamine has the larger overall evidence base for psychiatric use, built on hundreds of studies over more than two decades. Meta-analyses of this research report rapid antidepressant effects within hours of a single IV infusion, response rates of roughly 60 to 70 percent in treatment-resistant depression, and significant reductions in suicidal ideation. Because racemic ketamine has never gone through FDA approval for psychiatric conditions, this use remains off-label.

Esketamine's evidence base is narrower and comes primarily from the registration trials Janssen Pharmaceuticals conducted for FDA approval. The TRANSFORM trials showed statistically significant improvement in depression scores compared to placebo, though the company-reported effect sizes were modest in some of the studies. The ASPIRE trials showed rapid symptom improvement in patients with acute suicidal ideation, and the SUSTAIN trials found that continued esketamine treatment reduced relapse risk during long-term follow-up.

Direct head-to-head comparisons remain limited. A 2021 meta-analysis published in JAMA Psychiatry reported that IV racemic ketamine produced somewhat larger acute antidepressant effect sizes than intranasal esketamine, though the study authors cautioned that differences in route of administration, dosing, and patient populations complicated any direct comparison. A 2023 randomized trial comparing the two found superior antidepressant efficacy for IV racemic ketamine at 24 hours, with that difference narrowing over the following days. Researchers have debated whether this reflects a true pharmacological advantage or simply the higher bioavailability of IV administration compared with an intranasal spray; see our bioavailability explainer for how delivery route affects how much drug reaches the bloodstream.

The most consequential practical difference between the two forms is regulatory status. Esketamine is an FDA-approved product with a standardized formulation, dosing protocol, and the Risk Evaluation and Mitigation Strategy (REMS) safety program built around it. According to MedlinePlus, a consumer drug information service maintained by the U.S. National Library of Medicine, esketamine nasal spray must be administered under direct observation in a certified healthcare setting because of its sedation and dissociation risks, with monitoring for at least two hours after each dose.

Racemic ketamine is FDA-approved only as an anesthetic. Its use for depression, PTSD, or other psychiatric conditions is entirely off-label, with no standardized protocol, no REMS requirement, and no FDA-mandated monitoring framework. Oversight instead depends on the individual clinic or prescriber.

Arketamine, the R-enantiomer left out of Spravato, is drawing increasing research interest of its own. Preclinical studies have shown that arketamine produces longer-lasting antidepressant effects than esketamine in animal models, with less dissociation and fewer psychotomimetic effects. Its mechanism may rely more on AMPA receptor activation and BDNF release than on NMDA receptor blockade, which is the primary mechanism attributed to esketamine.

A Phase 2 clinical trial of arketamine (PCN-101) has reported early positive results in treatment-resistant depression, though this research is still preliminary and has not led to FDA approval. If arketamine continues to show benefit on its own, it raises a real question for the field: racemic ketamine, which already contains both enantiomers, may offer therapeutic advantages that esketamine alone cannot, simply by delivering both the S- and R-forms together. That remains a hypothesis rather than a settled conclusion, and more head-to-head research is needed before it can be confirmed.

When esketamine may be preferred:

• Insurance coverage is available, making the out-of-pocket cost manageable
• The patient values a standardized, FDA-approved protocol with defined dosing
• The prescriber and patient prefer the structure of the REMS monitoring program
• The patient meets the specific FDA-approved indication for treatment-resistant depression or suicidal ideation

When racemic ketamine may be preferred:

• The patient does not have insurance coverage for Spravato
• The clinician and patient want more flexibility in dosing and route of administration
• IV administration is preferred for its higher bioavailability and easier dose titration
• The patient is being treated for a condition other than treatment-resistant depression, such as chronic pain or PTSD, where racemic ketamine has a broader evidence base
• Integrating treatment with ketamine-assisted psychotherapy is a priority

Compounded racemic ketamine, discussed in our compounding pharmacy guide, carries its own oversight and quality considerations that differ from both IV racemic ketamine and Spravato. For a broader look at whether either option fits your situation, see our guide on who is a good candidate for ketamine treatment.

• MedlinePlus: Esketamine Nasal Spray, National Library of Medicine drug information on Spravato's pharmacology and approved indications
• MedlinePlus: Ketamine Injection, drug information on racemic ketamine's clinical uses and pharmacological profile
• StatPearls: Ketamine, a clinical reference on ketamine enantiomers, metabolism, and clinical considerations
• A National Institutes of Health-published pharmacology review comparing enantiomer receptor binding profiles